Taisho Pharmaceutical Holdings Co., Ltd.
TAIPY · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $29,498,000 | $21,398,000 | $22,976,000 | $30,311,000 |
| Dep. & Amort. | $24,648,000 | $23,074,000 | $22,041,000 | $16,695,000 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $0 | $0 | $0 |
| Change in WC | -$1,256,000 | $1,554,000 | $3,155,000 | $7,313,000 |
| Other Non-Cash | -$11,918,000 | -$17,520,000 | -$6,146,000 | -$12,327,000 |
| Operating Cash Flow | $40,972,000 | $28,506,000 | $42,026,000 | $41,992,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$50,379,000 | -$14,389,000 | -$14,372,000 | -$9,121,000 |
| Net Acquisitions | $1,512,000 | -$4,310,000 | -$4,084,000 | -$160,497,000 |
| Inv. Purchases | -$3,413,000 | -$1,269,000 | -$2,068,000 | -$1,858,000 |
| Inv. Sales/Matur. | $7,333,000 | $9,272,000 | $14,039,000 | $74,611,000 |
| Other Inv. Act. | $17,817,000 | $3,633,000 | $4,527,000 | -$10,216,000 |
| Investing Cash Flow | -$27,130,000 | -$7,063,000 | -$1,958,000 | -$107,081,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$622,000 | $95,000 | -$183,000 | -$1,264,000 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$34,000 | -$43,000 | -$41,000 | -$48,000 |
| Dividends Paid | -$8,206,000 | -$7,415,000 | -$8,787,000 | -$9,586,000 |
| Other Fin. Act. | -$2,015,000 | -$2,694,000 | -$2,335,000 | -$798,000 |
| Financing Cash Flow | -$10,877,000 | -$10,057,000 | -$11,346,000 | -$11,696,000 |
| Forex Effect | $1,595,000 | $780,000 | -$317,000 | $177,000 |
| Net Chg. in Cash | $4,561,000 | $12,166,000 | $28,405,000 | -$76,608,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $227,512,000 | $215,346,000 | $186,941,000 | $263,549,000 |
| End Cash | $232,073,000 | $227,512,000 | $215,346,000 | $186,941,000 |
| Free Cash Flow | -$9,407,000 | $14,117,000 | $27,654,000 | $32,871,000 |